Is the Diagnostics sector outperforming NIFTY 500?
The 52-week sector comparison is unavailable. 4 of 8 covered companies currently have positive Mansfield relative strength versus NIFTY 500.
20-quarter listed-company comparison
Diagnostics Stocks in India
Diagnostics: Dr Lal Pathlabs Ltd owns the largest revenue base; One Global Service Provider Ltd has the fastest current growth.
Nifty Diagnostics Index — Constituents & Performance
The Diagnostics companies below are the listed Indian Diagnostics universe this page tracks — the same constituent set people search for as the Nifty Diagnostics index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
The sector itself · before any single company
How has Diagnostics moved against NIFTY 500?
The line below covers 5.1 years. Over the most recent two of them this sector is 66% ahead of NIFTY 500. Earnings across its companies grew 24% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 13 weeks running.
LEADER · ahead 13w✓Price and the fundamentals both up5 of 8 companies ahead of NIFTY 500 by 5% or more over three months1 is 20% or more behind over a year while earnings grew 20% or more
RS ↑13w · 6/8 >200d (+0) · 5/8 lead (−1) · EPS 7/8↑
Diagnostics, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Strength anatomy
Broad but lateHow much of the sector is participating, how recently, and whether the movers score well.
Together5 of 8 stocks moving
Fresh0 crossed in the last 4 weeks
Backed by scoresmovers score +5 vs the sector average
Down the cap ladder — bar is now, tick is four weeks ago
Large
2/20
Mid
3/30
Small
0/3−1
Participation is not spreading downward this month; the larger companies are still carrying most of it.
Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 8 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
Sector relative strength · before individual stocks
Is Diagnostics outperforming NIFTY 500?
The 52-week comparison of Diagnostics against NIFTY 500 is not available from the current market series. 4 of 8 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Vijaya Diagnostic Centre Ltd is the strongest against the sector itself at +15.2%. Readings are as of 2026-07-19.
—Sector vs NIFTY 500 · 13 weeks
—Sector vs NIFTY 500 · 52 weeks
4/8Stocks leading NIFTY 500
4/8Stocks leading sector
Sector metric: 23.2 as of 2026-07-19 · CONSOLIDATION · falling.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
The 52-week sector comparison is unavailable. 4 of 8 covered companies currently have positive Mansfield relative strength versus NIFTY 500. Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 9 of 9 comparable companies through Jun 2026. One Global Service Provider Ltd has the fastest current revenue growth at 100%, across 9 of 9 comparable companies.
Which Diagnostics company is largest by revenue?
Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 9 of 9 comparable companies through Jun 2026.
Which Diagnostics company is growing fastest?
One Global Service Provider Ltd has the fastest current revenue growth at 100%, across 9 of 9 comparable companies.
Which Diagnostics company has the strongest 4-Factor Sector Score?
Thyrocare Technologies Ltd ranks first at 74/100 with 97% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Diagnostics company reports the most CAPEX?
Thyrocare Technologies Ltd reports the largest latest CAPEX at ₹15 crore, with 2 of 9 companies comparable.
Which Diagnostics company has the least gross debt?
One Global Service Provider Ltd has the lowest comparable gross debt at ₹0 crore. Krsnaa Diagnostics Ltd has the highest at ₹534 crore.
Which Diagnostics company has the lowest comparable PEG?
Thyrocare Technologies Ltd has the lowest comparable Guarded PEG at 1.1, among 3 of 9 companies that pass the metric’s comparability rules.
How much history does this Diagnostics comparison include?
The page compares up to 20 reported quarters per company for fundamentals, CAPEX, debt and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Companies
9
complete canonical membership
Combined market value
₹72.9K Cr
Dr Lal Pathlabs Ltd
Revenue growing
9/9
positive TTM year-on-year growth
Beating NIFTY 500
4/8
positive Mansfield relative strength
Global company selection
00 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Thyrocare Technologies Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 97% evidence confidence.
Krsnaa Diagnostics Ltd looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is guarded: positive earnings, positive 5–60% three-year EPS growth, and a positive P/E are required.
1. Thyrocare Technologies Ltd · THYROCARE
74.0/100 · Favorable setup · 97% evidence
Exact sum: 27.4 + 16.9 + 12.3 + 17.4 = 74
Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
27.4/35Growth & earnings
Revenue 21.3% · PAT 67.6% · OPM change 2 pp
95% evidence
16.9/25Capital efficiency
ROCE 35.4% · debt/equity 0.09×
95% evidence
12.3/20Valuation
P/E 49.7× · PEG 1.1
100% evidence
17.4/20Relative strength
RS sector 9.2% · RS bench 16.8% · 1Y 31.9%
100% evidence
2. One Global Service Provider Ltd · 514330
66.2/100 · Favorable setup · 79% evidence
Exact sum: 24.9 + 18.4 + 10.2 + 12.7 = 66.2
Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
24.9/35Growth & earnings
Revenue 100% · PAT 100% · OPM change -8 pp
83% evidence
18.4/25Capital efficiency
ROCE 87% · debt/equity 0×
80% evidence
10.2/20Valuation
P/E 16.6× · PEG —
50% evidence
12.7/20Relative strength
RS sector 14.2% · RS bench 21.9% · 1Y 135.5%
100% evidence
3. Metropolis Healthcare Ltd · METROPOLIS
63.4/100 · Mixed-positive evidence · 96% evidence
Exact sum: 27.2 + 15.2 + 7.9 + 13.1 = 63.4
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27.2/35Growth & earnings
Revenue 23.7% · PAT 31.7% · OPM change 7 pp
88% evidence
15.2/25Capital efficiency
ROCE 17.8% · debt/equity 0.15×
100% evidence
7.9/20Valuation
P/E 60.2× · PEG 2.34
100% evidence
13.1/20Relative strength
RS sector 0.9% · RS bench 8.3% · 1Y 12.5%
100% evidence
4. Vijaya Diagnostic Centre Ltd · VIJAYA
61.4/100 · Mixed-positive evidence · 93% evidence
Exact sum: 20 + 15.9 + 6.3 + 19.2 = 61.4
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20.0/35Growth & earnings
Revenue 19.5% · PAT 20.1% · OPM change 4 pp
83% evidence
15.9/25Capital efficiency
ROCE 21.3% · debt/equity 0.44×
95% evidence
6.3/20Valuation
P/E 78.2× · PEG 1.46
100% evidence
19.2/20Relative strength
RS sector 15.2% · RS bench 23.2% · 1Y 30.5%
100% evidence
5. Dr Lal Pathlabs Ltd · 539524
52.2/100 · Thin evidence · provisional · 56% evidence
Exact sum: 14.8 + 18.1 + 9.3 + 10 = 52.2
Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14.8/35Growth & earnings
Revenue 14.3% · PAT 5% · OPM change 2 pp
95% evidence
18.1/25Capital efficiency
ROCE 28% · debt/equity 0.08×
80% evidence
9.3/20Valuation
P/E 54.6× · PEG —
15% evidence
10.0/20Relative strength
RS sector — · RS bench — · 1Y —
0% evidence
6. 3B Blackbio DX Ltd · 3BBLACKBIO
48.4/100 · Mixed-negative evidence · 83% evidence
Exact sum: 15.2 + 16.6 + 11.5 + 5.1 = 48.4
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15.2/35Growth & earnings
Revenue 47.1% · PAT 25.7% · OPM change -11.2 pp
83% evidence
16.6/25Capital efficiency
ROCE 25.5% · debt/equity 0.01×
95% evidence
11.5/20Valuation
P/E 18.7× · PEG —
50% evidence
5.1/20Relative strength
RS sector -15.7% · RS bench -9.3% · 1Y -18.7%
100% evidence
7. Krsnaa Diagnostics Ltd · KRSNAA
40.8/100 · Mixed-negative evidence · 77% evidence
Exact sum: 13.4 + 9.1 + 14.5 + 3.8 = 40.8
Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
13.4/35Growth & earnings
Revenue 7.8% · PAT 30.8% · OPM change 0 pp
83% evidence
9.1/25Capital efficiency
ROCE 12.7% · debt/equity 0.55×
95% evidence
14.5/20Valuation
P/E 17.4× · PEG —
50% evidence
3.8/20Relative strength
RS sector -18.5% · RS bench -22.5% · 1Y -36.1%
70% evidence
8. Suraksha Diagnostic Ltd · SURAKSHA
38.5/100 · Mixed-negative evidence · 76% evidence
Exact sum: 13.8 + 11.4 + 10.4 + 2.9 = 38.5
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13.8/35Growth & earnings
Revenue 23.1% · PAT 1.4% · OPM change 0.5 pp
83% evidence
11.4/25Capital efficiency
ROCE 17% · debt/equity 0.53×
95% evidence
10.4/20Valuation
P/E 40.9× · PEG —
15% evidence
2.9/20Relative strength
RS sector -16.4% · RS bench -10.2% · 1Y -19%
100% evidence
9. Vimta Labs Ltd · VIMTALABS
44.4/100 · Thin evidence · provisional · 45% evidence
Exact sum: 17.5 + 14.7 + 7.6 + 4.6 = 44.4
Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17.5/35Growth & earnings
Revenue 7.8% · PAT 48.8% · OPM change 5 pp
18% evidence
14.7/25Capital efficiency
ROCE 17.6% · debt/equity 0.04×
60% evidence
7.6/20Valuation
P/E 41.9× · PEG —
50% evidence
4.6/20Relative strength
RS sector -21.9% · RS bench -3.6% · 1Y 6.4%
70% evidence
01 · compare level, then change
Revenue Scale & Growth Durability
Dr Lal Pathlabs Ltd has the highest Revenue among the 9 Diagnostics companies compared here, at ₹2,892 crore. Metropolis Healthcare Ltd is next at ₹1,646 crore. One Global Service Provider Ltd has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Dr Lal Pathlabs Ltd is the scale leader at ₹2,892 crore, 75.7% ahead of Metropolis Healthcare Ltd. One Global Service Provider Ltd's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 311.6% from a ₹498 crore base, with 15 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderDr Lal Pathlabs Ltd · ₹2,892 crore
Gap75.7% versus #2 · Metropolis Healthcare Ltd
Persistence8/8 recent comparable periods
Coverage9/9 companies · 140 observations
Investor read: Dr Lal Pathlabs Ltd is the scale benchmark; One Global Service Provider Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Dr Lal Pathlabs Ltd's growth falls below One Global Service Provider Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Dr Lal Pathlabs Ltd 539524₹2.9K Cr
2Metropolis Healthcare Ltd METROPOLIS₹1.6K Cr
3Thyrocare Technologies Ltd THYROCARE₹877 Cr
4Vijaya Diagnostic Centre Ltd VIJAYA₹814 Cr
5Krsnaa Diagnostics Ltd KRSNAA⚠ unverified₹773 Cr
Revenue growthfastest growers
1One Global Service Provider Ltd 514330100%
23B Blackbio DX Ltd 3BBLACKBIO⚠ unverified47%
3Metropolis Healthcare Ltd METROPOLIS24%
4Suraksha Diagnostic Ltd SURAKSHA⚠ unverified23%
5Thyrocare Technologies Ltd THYROCARE21%
Revenue · company comparison
9/9 level · 9/9 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Dr Lal Pathlabs Ltd 539524 | ₹798 Cr | 19% | Jun 2026 |
| Metropolis Healthcare Ltd METROPOLIS | ₹425 Cr | 23% | Mar 2026 |
| Thyrocare Technologies Ltd THYROCARE | ₹240 Cr | 24% | Jun 2026 |
| Vijaya Diagnostic Centre Ltd VIJAYA | ₹219 Cr | 27% | Mar 2026 |
| Krsnaa Diagnostics Ltd KRSNAA⚠ unverified | ₹193 Cr | 3.8% | Mar 2026 |
| One Global Service Provider Ltd 514330 | ₹134 Cr | 144% | Mar 2026 |
| Vimta Labs Ltd VIMTALABS | ₹90 Cr | 20% | Dec 2024 |
| Suraksha Diagnostic Ltd SURAKSHA⚠ unverified | ₹81 Cr | 25% | Mar 2026 |
| 3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified | ₹35 Cr | 57% | Mar 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
—
—
—
—
—
₹15 Cr
₹18 Cr
₹14 Cr
₹19 Cr
₹18 Cr
₹23 Cr
₹19 Cr
₹29 Cr
₹25 Cr
₹23 Cr
₹22 Cr
₹34 Cr
₹50 Cr
₹35 Cr
—
Dr Lal Pathlabs Ltd · 539524
—
—
—
—
—
₹429 Cr
₹431 Cr
₹541 Cr
₹601 Cr
₹539 Cr
₹545 Cr
₹602 Cr
₹660 Cr
₹597 Cr
₹603 Cr
₹670 Cr
₹731 Cr
₹660 Cr
₹703 Cr
₹798 Cr
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
—
—
—
—
—
₹118 Cr
₹133 Cr
₹140 Cr
₹155 Cr
₹158 Cr
₹166 Cr
₹170 Cr
₹186 Cr
₹175 Cr
₹186 Cr
₹193 Cr
₹206 Cr
₹181 Cr
₹193 Cr
—
Metropolis Healthcare Ltd · METROPOLIS
₹303 Cr
₹293 Cr
₹306 Cr
₹280 Cr
₹300 Cr
₹285 Cr
₹283 Cr
₹277 Cr
₹308 Cr
₹291 Cr
₹331 Cr
₹313 Cr
₹350 Cr
₹323 Cr
₹345 Cr
₹386 Cr
₹429 Cr
₹406 Cr
₹425 Cr
—
One Global Service Provider Ltd · 514330
—
—
—
—
₹3 Cr
₹8 Cr
₹5 Cr
₹13 Cr
₹12 Cr
₹15 Cr
₹24 Cr
₹14 Cr
₹19 Cr
₹33 Cr
₹55 Cr
₹88 Cr
₹135 Cr
₹141 Cr
₹134 Cr
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
₹60 Cr
₹52 Cr
₹55 Cr
₹61 Cr
₹67 Cr
₹60 Cr
₹65 Cr
₹73 Cr
₹79 Cr
₹78 Cr
₹81 Cr
—
Thyrocare Technologies Ltd · THYROCARE
₹176 Cr
₹117 Cr
₹131 Cr
₹128 Cr
₹135 Cr
₹128 Cr
₹136 Cr
₹135 Cr
₹148 Cr
₹135 Cr
₹154 Cr
₹157 Cr
₹177 Cr
₹166 Cr
₹187 Cr
₹193 Cr
₹217 Cr
₹196 Cr
₹224 Cr
₹240 Cr
Vijaya Diagnostic Centre Ltd · VIJAYA
₹113 Cr
₹111 Cr
₹116 Cr
₹104 Cr
₹121 Cr
₹113 Cr
₹121 Cr
₹121 Cr
₹139 Cr
₹133 Cr
₹155 Cr
₹156 Cr
₹183 Cr
₹169 Cr
₹173 Cr
₹188 Cr
₹202 Cr
₹205 Cr
₹219 Cr
—
Vimta Labs Ltd · VIMTALABS
—
₹67 Cr
₹74 Cr
₹79 Cr
₹80 Cr
₹77 Cr
₹82 Cr
₹83 Cr
₹66 Cr
₹75 Cr
₹80 Cr
₹75 Cr
₹85 Cr
₹90 Cr
—
—
—
—
—
—
Revenue growth · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
—
—
—
—
—
—
—
—
—
18%
27%
36%
52%
44%
-2.2%
14%
16%
98%
57%
—
Dr Lal Pathlabs Ltd · 539524
—
—
—
—
—
—
—
—
—
26%
26%
11%
9.8%
11%
11%
11%
11%
11%
17%
19%
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
—
—
—
—
—
—
—
—
—
34%
25%
21%
20%
11%
12%
14%
11%
3.4%
3.8%
—
Metropolis Healthcare Ltd · METROPOLIS
—
—
—
-14%
-1.0%
-2.7%
-7.5%
-1.1%
2.7%
2.1%
17%
13%
14%
11%
4.2%
23%
23%
26%
23%
—
One Global Service Provider Ltd · 514330
—
—
—
—
—
—
—
—
300%
88%
380%
7.7%
58%
120%
129%
529%
611%
327%
144%
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
11%
15%
18%
20%
18%
31%
25%
—
Thyrocare Technologies Ltd · THYROCARE
—
—
—
-22%
-23%
9.4%
3.8%
5.5%
9.6%
5.5%
13%
16%
20%
23%
21%
23%
23%
18%
20%
24%
Vijaya Diagnostic Centre Ltd · VIJAYA
—
—
—
-15%
7.1%
1.8%
4.3%
16%
15%
18%
28%
29%
32%
27%
12%
21%
10%
21%
27%
—
Vimta Labs Ltd · VIMTALABS
—
—
—
—
—
15%
11%
5.1%
-18%
-2.6%
-2.4%
-9.6%
29%
20%
—
—
—
—
—
—
02 · compare level, then change
Operating Economics & Margin Trend
Vijaya Diagnostic Centre Ltd has the highest OPM among the 9 Diagnostics companies compared here, at 44%. Vimta Labs Ltd is next at 37%. Metropolis Healthcare Ltd has the highest Margin change at +7 percentage points, so level and change sit with different companies. 9 of 9 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Vijaya Diagnostic Centre Ltd leads opm at 44%; Metropolis Healthcare Ltd leads margin change at +7 percentage points.
LeaderVijaya Diagnostic Centre Ltd · 44%
Gap18.9% versus #2 · Vimta Labs Ltd
Persistence4/8 recent comparable periods
Coverage9/9 companies · 160 observations
Investor read: Vijaya Diagnostic Centre Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Vijaya Diagnostic Centre Ltd VIJAYA44%
2Vimta Labs Ltd VIMTALABS · older report37%
3Thyrocare Technologies Ltd THYROCARE32%
4Dr Lal Pathlabs Ltd 53952431%
5Suraksha Diagnostic Ltd SURAKSHA⚠ unverified30%
Margin changefastest expanders
1Metropolis Healthcare Ltd METROPOLIS+7.0 pp
2Vimta Labs Ltd VIMTALABS · older report+5.0 pp
3Vijaya Diagnostic Centre Ltd VIJAYA+4.0 pp
4Dr Lal Pathlabs Ltd 539524+2.0 pp
5Thyrocare Technologies Ltd THYROCARE+2.0 pp
Operating margin · company comparison
9/9 level · 9/9 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Vijaya Diagnostic Centre Ltd VIJAYA | 44% | +4.0 pp | Mar 2026 |
| Vimta Labs Ltd VIMTALABS | 37% | +5.0 pp | Dec 2024 |
| Thyrocare Technologies Ltd THYROCARE | 32% | +2.0 pp | Jun 2026 |
| Dr Lal Pathlabs Ltd 539524 | 31% | +2.0 pp | Jun 2026 |
| Suraksha Diagnostic Ltd SURAKSHA⚠ unverified | 30% | +0.5 pp | Mar 2026 |
| Krsnaa Diagnostics Ltd KRSNAA⚠ unverified | 28% | 0.0 pp | Mar 2026 |
| Metropolis Healthcare Ltd METROPOLIS | 25% | +7.0 pp | Mar 2026 |
| 3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified | 24% | −11.2 pp | Mar 2026 |
| One Global Service Provider Ltd 514330 | 18% | −8.0 pp | Mar 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
39%
49%
32%
44%
53%
50%
41%
45%
41%
50%
43%
56%
55%
59%
35%
53%
43%
43%
24%
—
Dr Lal Pathlabs Ltd · 539524
28%
22%
25%
23%
27%
24%
27%
27%
30%
26%
27%
28%
31%
26%
28%
29%
31%
27%
27%
31%
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
29%
28%
26%
25%
25%
25%
26%
22%
20%
24%
26%
25%
27%
26%
28%
27%
29%
26%
28%
—
Metropolis Healthcare Ltd · METROPOLIS
30%
26%
24%
24%
26%
25%
25%
23%
24%
22%
24%
25%
26%
22%
18%
23%
25%
23%
25%
—
One Global Service Provider Ltd · 514330
21%
32%
33%
9.1%
9.0%
9.0%
10%
11%
8.0%
14%
22%
17%
16%
14%
26%
15%
19%
21%
18%
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
35%
30%
35%
34%
35%
31%
29%
33%
31%
30%
30%
—
Thyrocare Technologies Ltd · THYROCARE
51%
31%
29%
28%
23%
22%
18%
26%
25%
23%
22%
27%
27%
25%
30%
30%
33%
30%
34%
32%
Vijaya Diagnostic Centre Ltd · VIJAYA
45%
43%
41%
38%
40%
39%
41%
40%
41%
39%
41%
39%
42%
40%
40%
39%
41%
42%
44%
—
Vimta Labs Ltd · VIMTALABS
26%
31%
31%
30%
32%
28%
30%
30%
27%
32%
31%
35%
35%
37%
—
—
—
—
—
—
Margin change · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
−31.7 pp
−10.0 pp
−12.9 pp
−11.4 pp
+13.6 pp
+1.5 pp
+9.0 pp
+0.8 pp
−12.4 pp
+0.2 pp
+1.8 pp
+11.3 pp
+14.9 pp
+9.2 pp
−7.8 pp
−3.1 pp
−12.0 pp
−16.2 pp
−11.2 pp
—
Dr Lal Pathlabs Ltd · 539524
−1.1 pp
−8.7 pp
−3.4 pp
−7.8 pp
−1.5 pp
+2.0 pp
+2.1 pp
+3.6 pp
+3.1 pp
+2.0 pp
0.0 pp
+1.0 pp
+1.0 pp
0.0 pp
+1.0 pp
+1.0 pp
0.0 pp
+1.0 pp
−1.0 pp
+2.0 pp
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
+1.0 pp
+9.1 pp
−8.8 pp
−6.7 pp
−4.6 pp
−3.2 pp
+0.1 pp
−2.6 pp
−4.9 pp
−1.0 pp
0.0 pp
+3.0 pp
+7.0 pp
+2.0 pp
+2.0 pp
+2.0 pp
+2.0 pp
0.0 pp
0.0 pp
—
Metropolis Healthcare Ltd · METROPOLIS
−1.7 pp
−5.8 pp
−8.6 pp
−6.9 pp
−3.5 pp
−0.7 pp
+0.5 pp
−1.5 pp
−2.3 pp
−3.0 pp
−1.0 pp
+2.0 pp
+2.0 pp
0.0 pp
−6.0 pp
−2.0 pp
−1.0 pp
+1.0 pp
+7.0 pp
—
One Global Service Provider Ltd · 514330
−75.7 pp
−32.1 pp
−29.0 pp
−0.8 pp
−12.0 pp
−23.4 pp
−22.8 pp
+1.9 pp
−1.0 pp
+5.0 pp
+12.0 pp
+6.0 pp
+8.0 pp
0.0 pp
+4.0 pp
−2.0 pp
+3.0 pp
+7.0 pp
−8.0 pp
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
+0.1 pp
+1.1 pp
−5.8 pp
−1.2 pp
−4.1 pp
−0.9 pp
+0.5 pp
—
Thyrocare Technologies Ltd · THYROCARE
+10.2 pp
−4.7 pp
−6.3 pp
−15.0 pp
−27.2 pp
−9.2 pp
−10.8 pp
−2.1 pp
+1.6 pp
+1.0 pp
+4.0 pp
+1.0 pp
+2.0 pp
+2.0 pp
+8.0 pp
+3.0 pp
+6.0 pp
+5.0 pp
+4.0 pp
+2.0 pp
Vijaya Diagnostic Centre Ltd · VIJAYA
+0.1 pp
−3.3 pp
−7.4 pp
−8.1 pp
−5.0 pp
−4.2 pp
−0.2 pp
+1.8 pp
+0.6 pp
0.0 pp
0.0 pp
−1.0 pp
+1.0 pp
+1.0 pp
−1.0 pp
0.0 pp
−1.0 pp
+2.0 pp
+4.0 pp
—
Vimta Labs Ltd · VIMTALABS
−0.5 pp
+2.6 pp
+3.1 pp
+2.8 pp
+5.6 pp
−3.0 pp
−1.0 pp
0.0 pp
−5.0 pp
+4.0 pp
+1.0 pp
+5.0 pp
+8.0 pp
+5.0 pp
—
—
—
—
—
—
03 · compare level, then change
Profit Scale & Acceleration
Dr Lal Pathlabs Ltd has the highest Net profit among the 9 Diagnostics companies compared here, at ₹545 crore. Metropolis Healthcare Ltd is next at ₹191 crore. One Global Service Provider Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Dr Lal Pathlabs Ltd leads with ₹545 crore of TTM profit, 185.3% above Metropolis Healthcare Ltd. One Global Service Provider Ltd shows ≥100% on the scoring scale (288.9% uncapped) growth from a ₹70 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderDr Lal Pathlabs Ltd · ₹545 crore
Gap185.3% versus #2 · Metropolis Healthcare Ltd
Persistence6/8 recent comparable periods
Coverage9/9 companies · 140 observations
Investor read: Dr Lal Pathlabs Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Dr Lal Pathlabs Ltd 539524₹545 Cr
2Metropolis Healthcare Ltd METROPOLIS₹191 Cr
3Thyrocare Technologies Ltd THYROCARE₹176 Cr
4Vijaya Diagnostic Centre Ltd VIJAYA₹173 Cr
5Krsnaa Diagnostics Ltd KRSNAA⚠ unverified₹102 Cr
Profit growthfastest growers
1One Global Service Provider Ltd 514330100%
2Thyrocare Technologies Ltd THYROCARE68%
3Vimta Labs Ltd VIMTALABS · older report49%
4Metropolis Healthcare Ltd METROPOLIS32%
5Krsnaa Diagnostics Ltd KRSNAA⚠ unverified31%
Net profit · company comparison
9/9 level · 9/9 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Dr Lal Pathlabs Ltd 539524 | ₹170 Cr | 27% | Jun 2026 |
| Metropolis Healthcare Ltd METROPOLIS | ₹51 Cr | 76% | Mar 2026 |
| Thyrocare Technologies Ltd THYROCARE | ₹51 Cr | 34% | Jun 2026 |
| Vijaya Diagnostic Centre Ltd VIJAYA | ₹48 Cr | 37% | Mar 2026 |
| Krsnaa Diagnostics Ltd KRSNAA⚠ unverified | ₹42 Cr | 100% | Mar 2026 |
| Vimta Labs Ltd VIMTALABS | ₹22 Cr | 120% | Dec 2024 |
| One Global Service Provider Ltd 514330 | ₹18 Cr | 64% | Mar 2026 |
| 3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified | ₹10 Cr | 22% | Mar 2026 |
| Suraksha Diagnostic Ltd SURAKSHA⚠ unverified | ₹6 Cr | -14% | Mar 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
—
—
—
—
—
₹8 Cr
₹5 Cr
₹7 Cr
₹8 Cr
₹9 Cr
₹9 Cr
₹11 Cr
₹15 Cr
₹13 Cr
₹8 Cr
₹13 Cr
₹15 Cr
₹22 Cr
₹10 Cr
—
Dr Lal Pathlabs Ltd · 539524
—
—
—
—
—
₹63 Cr
₹71 Cr
₹84 Cr
₹111 Cr
₹82 Cr
₹86 Cr
₹108 Cr
₹131 Cr
₹98 Cr
₹156 Cr
₹134 Cr
₹152 Cr
₹91 Cr
₹132 Cr
₹170 Cr
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
—
—
—
—
—
₹14 Cr
₹19 Cr
₹15 Cr
₹10 Cr
₹13 Cr
₹19 Cr
₹18 Cr
₹20 Cr
₹19 Cr
₹21 Cr
₹21 Cr
₹24 Cr
₹15 Cr
₹42 Cr
—
Metropolis Healthcare Ltd · METROPOLIS
₹58 Cr
₹41 Cr
₹40 Cr
₹33 Cr
₹40 Cr
₹36 Cr
₹33 Cr
₹29 Cr
₹36 Cr
₹27 Cr
₹37 Cr
₹38 Cr
₹47 Cr
₹31 Cr
₹29 Cr
₹45 Cr
₹53 Cr
₹42 Cr
₹51 Cr
—
One Global Service Provider Ltd · 514330
—
—
—
—
₹0 Cr
₹1 Cr
₹0 Cr
₹1 Cr
₹1 Cr
₹1 Cr
₹4 Cr
₹2 Cr
₹2 Cr
₹3 Cr
₹11 Cr
₹10 Cr
₹20 Cr
₹22 Cr
₹18 Cr
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
₹8 Cr
₹5 Cr
₹6 Cr
₹8 Cr
₹10 Cr
₹6 Cr
₹7 Cr
₹9 Cr
₹9 Cr
₹7 Cr
₹6 Cr
—
Thyrocare Technologies Ltd · THYROCARE
₹78 Cr
₹22 Cr
₹21 Cr
₹22 Cr
₹15 Cr
₹15 Cr
₹12 Cr
₹17 Cr
₹20 Cr
₹15 Cr
₹17 Cr
₹24 Cr
₹26 Cr
₹19 Cr
₹22 Cr
₹38 Cr
₹48 Cr
₹28 Cr
₹49 Cr
₹51 Cr
Vijaya Diagnostic Centre Ltd · VIJAYA
₹28 Cr
₹25 Cr
₹24 Cr
₹17 Cr
₹23 Cr
₹16 Cr
₹28 Cr
₹26 Cr
₹34 Cr
₹26 Cr
₹34 Cr
₹32 Cr
₹42 Cr
₹35 Cr
₹35 Cr
₹39 Cr
₹43 Cr
₹43 Cr
₹48 Cr
—
Vimta Labs Ltd · VIMTALABS
—
₹12 Cr
₹12 Cr
₹12 Cr
₹13 Cr
₹10 Cr
₹13 Cr
₹12 Cr
₹6 Cr
₹10 Cr
₹12 Cr
₹12 Cr
₹15 Cr
₹22 Cr
—
—
—
—
—
—
Profit growth · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
—
—
—
—
—
—
—
—
—
6.4%
69%
57%
96%
59%
-8.5%
12%
1.1%
66%
22%
—
Dr Lal Pathlabs Ltd · 539524
—
—
—
—
—
—
—
—
—
30%
21%
29%
18%
20%
81%
24%
16%
-7.1%
-15%
27%
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
—
—
—
—
—
—
—
—
—
-7.1%
0.0%
20%
100%
46%
11%
17%
20%
-21%
100%
—
Metropolis Healthcare Ltd · METROPOLIS
—
—
—
-56%
-31%
-12%
-18%
-12%
-10%
-25%
12%
31%
31%
15%
-22%
18%
13%
35%
76%
—
One Global Service Provider Ltd · 514330
—
—
—
—
—
—
—
—
—
0.0%
—
100%
100%
200%
175%
400%
900%
633%
64%
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
22%
32%
13%
20%
-13%
21%
-14%
—
Thyrocare Technologies Ltd · THYROCARE
—
—
—
-61%
-81%
-32%
-43%
-23%
33%
0.0%
42%
41%
30%
27%
29%
58%
85%
47%
123%
34%
Vijaya Diagnostic Centre Ltd · VIJAYA
—
—
—
-48%
-18%
-36%
17%
53%
48%
63%
21%
23%
24%
35%
2.9%
22%
2.4%
23%
37%
—
Vimta Labs Ltd · VIMTALABS
—
—
—
—
—
-17%
8.3%
0.0%
-54%
0.0%
-7.7%
0.0%
150%
120%
—
—
—
—
—
—
04 · compare level, then change
Capacity Spending & Returns On It
Thyrocare Technologies Ltd has the highest CAPEX among the 9 Diagnostics companies compared here, at ₹15 crore. Suraksha Diagnostic Ltd is next at ₹12 crore. Suraksha Diagnostic Ltd has the highest CAPEX intensity at 18%, so level and change sit with different companies. 2 of 9 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Thyrocare Technologies Ltd reports ₹15 crore of CAPEX; Suraksha Diagnostic Ltd has the highest covered intensity at 18%. Coverage is only 2 of 9 companies and 5 reported observations, so this is partial evidence—not a complete sector rank.
LeaderThyrocare Technologies Ltd · ₹15 crore
Gap25% versus #2 · Suraksha Diagnostic Ltd
Persistence1/1 recent comparable periods
Coverage2/9 companies · 5 observations
Investor read: Use the CAPEX rank as a diligence queue. Verify commissioning, utilization, cash conversion and post-investment ROCE before treating spend as value creation.
This conclusion weakens if: CAPEX rises without higher utilization, operating cash flow or incremental returns.
CAPEX is cash spent on property, plant, equipment and other reported capital assets. CAPEX intensity divides that spend by revenue; high intensity is a reinvestment signal, not proof that the reinvestment will earn attractive returns.
CAPEXlargest spenders
1Thyrocare Technologies Ltd THYROCARE₹15 Cr
2Suraksha Diagnostic Ltd SURAKSHA⚠ unverified₹12 Cr
CAPEX intensityhighest reinvestment intensity
1Suraksha Diagnostic Ltd SURAKSHA⚠ unverified18%
2Thyrocare Technologies Ltd THYROCARE8.5%
Capital expenditure · company comparison
2/9 level · 2/9 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
Withheld from this chart: Vimta Labs Ltd (VIMTALABS) — its two data sources disagree by up to 64% on reported income across 13 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | CAPEX | CAPEX intensity | Reported |
|---|---|---|---|
| Thyrocare Technologies Ltd THYROCARE | ₹15 Cr | 8.5% | Jun 2026 |
| Suraksha Diagnostic Ltd SURAKSHA⚠ unverified | ₹12 Cr | 18% | Mar 2026 |
Full 20-quarter history · every available company
CAPEX · reported quarter history
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
₹15 Cr
₹15 Cr
—
—
₹7 Cr
₹12 Cr
—
—
—
—
—
—
—
Thyrocare Technologies Ltd · THYROCARE
₹15 Cr
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
CAPEX intensity · reported quarter history
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
25%
—
—
12%
18%
—
—
—
—
—
—
—
Thyrocare Technologies Ltd · THYROCARE
8.5%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Annual capital allocation · 10-year view
9/9 capacity base · 9/9 OCF · 9/9 CAPEX · 9/9 FCF
Capacity base is net fixed assets plus capital work in progress, straight off the reported balance sheet. It is not cash spent, so it answers a narrower question than CAPEX — but it is reported for companies whose cash-flow CAPEX is not published, which is why it leads here. Missing years remain blank; annual values are never relabelled as quarters.
Full annual capacity base, operating cash flow, CAPEX and free cash flow history
Capacity base · net fixed assets + CWIP · fiscal-year history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
₹3 Cr
₹4 Cr
₹4 Cr
₹4 Cr
₹5 Cr
₹7 Cr
₹8 Cr
₹7 Cr
₹7 Cr
₹28 Cr
Dr Lal Pathlabs Ltd · 539524
₹170 Cr
₹218 Cr
₹212 Cr
₹424 Cr
₹457 Cr
₹1.4K Cr
₹1.3K Cr
₹1.2K Cr
₹1.2K Cr
₹1.3K Cr
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
₹137 Cr
—
₹265 Cr
₹284 Cr
₹313 Cr
₹414 Cr
₹496 Cr
₹657 Cr
₹673 Cr
₹864 Cr
Metropolis Healthcare Ltd · METROPOLIS
₹203 Cr
₹207 Cr
₹219 Cr
₹299 Cr
₹343 Cr
₹1.1K Cr
₹1.1K Cr
₹1.2K Cr
₹1.4K Cr
₹1.6K Cr
One Global Service Provider Ltd · 514330
₹3 Cr
₹3 Cr
₹3 Cr
₹3 Cr
₹4 Cr
₹4 Cr
₹4 Cr
₹4 Cr
₹2 Cr
₹2 Cr
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
₹128 Cr
₹119 Cr
₹120 Cr
₹197 Cr
₹213 Cr
₹234 Cr
₹351 Cr
Thyrocare Technologies Ltd · THYROCARE
₹276 Cr
₹299 Cr
₹295 Cr
₹274 Cr
₹261 Cr
₹288 Cr
₹296 Cr
₹309 Cr
₹311 Cr
₹320 Cr
Vijaya Diagnostic Centre Ltd · VIJAYA
—
₹122 Cr
₹262 Cr
₹282 Cr
₹277 Cr
₹404 Cr
₹552 Cr
₹751 Cr
₹935 Cr
₹1.1K Cr
Vimta Labs Ltd · VIMTALABS
—
—
—
₹140 Cr
₹152 Cr
₹169 Cr
₹187 Cr
₹230 Cr
—
—
Operating cash flow · fiscal-year history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
₹1 Cr
₹2 Cr
₹4 Cr
₹7 Cr
₹98 Cr
₹37 Cr
₹20 Cr
₹27 Cr
₹43 Cr
₹52 Cr
Dr Lal Pathlabs Ltd · 539524
₹171 Cr
₹197 Cr
₹219 Cr
₹284 Cr
₹398 Cr
₹447 Cr
₹456 Cr
₹535 Cr
₹569 Cr
₹636 Cr
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
₹64 Cr
—
₹61 Cr
₹38 Cr
₹119 Cr
₹128 Cr
₹76 Cr
₹24 Cr
₹87 Cr
₹143 Cr
Metropolis Healthcare Ltd · METROPOLIS
₹102 Cr
₹104 Cr
₹90 Cr
₹215 Cr
₹249 Cr
₹253 Cr
₹247 Cr
₹264 Cr
₹263 Cr
₹351 Cr
One Global Service Provider Ltd · 514330
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹1 Cr
₹1 Cr
₹0 Cr
₹1 Cr
₹14 Cr
₹3 Cr
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
₹31 Cr
₹24 Cr
₹42 Cr
₹44 Cr
₹60 Cr
₹63 Cr
₹82 Cr
Thyrocare Technologies Ltd · THYROCARE
₹90 Cr
₹107 Cr
₹100 Cr
₹168 Cr
₹115 Cr
₹113 Cr
₹129 Cr
₹168 Cr
₹191 Cr
₹213 Cr
Vijaya Diagnostic Centre Ltd · VIJAYA
—
₹62 Cr
₹91 Cr
₹106 Cr
₹130 Cr
₹158 Cr
₹165 Cr
₹183 Cr
₹224 Cr
₹271 Cr
Vimta Labs Ltd · VIMTALABS
—
—
—
₹24 Cr
₹37 Cr
₹59 Cr
₹88 Cr
₹61 Cr
—
—
CAPEX · reported cash flow · fiscal-year history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
₹0 Cr
₹1 Cr
₹1 Cr
₹1 Cr
₹2 Cr
₹3 Cr
₹2 Cr
₹0 Cr
₹1 Cr
₹26 Cr
Dr Lal Pathlabs Ltd · 539524
₹28 Cr
₹81 Cr
₹32 Cr
₹285 Cr
₹110 Cr
₹1.0K Cr
₹76 Cr
₹68 Cr
₹79 Cr
₹254 Cr
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
₹55 Cr
—
—
₹51 Cr
₹66 Cr
₹142 Cr
₹136 Cr
₹236 Cr
₹104 Cr
₹281 Cr
Metropolis Healthcare Ltd · METROPOLIS
₹77 Cr
₹23 Cr
₹32 Cr
₹119 Cr
₹90 Cr
₹785 Cr
₹165 Cr
₹130 Cr
₹379 Cr
₹288 Cr
One Global Service Provider Ltd · 514330
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹1 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹-1 Cr
₹1 Cr
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
₹7 Cr
₹16 Cr
₹109 Cr
₹49 Cr
₹56 Cr
₹158 Cr
Thyrocare Technologies Ltd · THYROCARE
₹34 Cr
₹43 Cr
₹22 Cr
₹11 Cr
₹17 Cr
₹61 Cr
₹47 Cr
₹60 Cr
₹57 Cr
₹68 Cr
Vijaya Diagnostic Centre Ltd · VIJAYA
—
—
₹180 Cr
₹69 Cr
₹45 Cr
₹180 Cr
₹210 Cr
₹256 Cr
₹255 Cr
₹261 Cr
Vimta Labs Ltd · VIMTALABS
—
—
—
—
₹35 Cr
₹40 Cr
₹49 Cr
₹77 Cr
—
—
Free cash flow · fiscal-year history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
₹1 Cr
₹1 Cr
₹3 Cr
₹6 Cr
₹96 Cr
₹34 Cr
₹18 Cr
₹27 Cr
₹42 Cr
₹26 Cr
Dr Lal Pathlabs Ltd · 539524
₹143 Cr
₹116 Cr
₹187 Cr
₹-1 Cr
₹288 Cr
₹-588 Cr
₹380 Cr
₹467 Cr
₹490 Cr
₹382 Cr
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
₹9 Cr
—
—
₹-13 Cr
₹53 Cr
₹-14 Cr
₹-60 Cr
₹-212 Cr
₹-17 Cr
₹-138 Cr
Metropolis Healthcare Ltd · METROPOLIS
₹25 Cr
₹81 Cr
₹58 Cr
₹96 Cr
₹159 Cr
₹-532 Cr
₹82 Cr
₹134 Cr
₹-116 Cr
₹63 Cr
One Global Service Provider Ltd · 514330
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹1 Cr
₹0 Cr
₹1 Cr
₹15 Cr
₹2 Cr
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
₹17 Cr
₹26 Cr
₹-65 Cr
₹11 Cr
₹7 Cr
₹-76 Cr
Thyrocare Technologies Ltd · THYROCARE
₹56 Cr
₹64 Cr
₹78 Cr
₹157 Cr
₹98 Cr
₹52 Cr
₹82 Cr
₹108 Cr
₹134 Cr
₹145 Cr
Vijaya Diagnostic Centre Ltd · VIJAYA
—
—
₹-89 Cr
₹37 Cr
₹85 Cr
₹-22 Cr
₹-45 Cr
₹-73 Cr
₹-31 Cr
₹10 Cr
Vimta Labs Ltd · VIMTALABS
—
—
—
—
₹2 Cr
₹19 Cr
₹39 Cr
₹-16 Cr
—
—
05 · compare level, then change
Debt Load & Balance-Sheet Headroom
One Global Service Provider Ltd has the lowest Gross debt among the 9 Diagnostics companies compared here, at ₹0 crore. 3B Blackbio DX Ltd is next at ₹3 crore. Thyrocare Technologies Ltd has the lowest Net debt at ₹139 crore net cash, so level and change sit with different companies.
What the numbers say: Thyrocare Technologies Ltd has the clearest covered balance-sheet capacity with ₹139 crore net cash and gross debt of ₹51 crore. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.
LeaderOne Global Service Provider Ltd · ₹0 crore
Gap100% versus #2 · 3B Blackbio DX Ltd
PersistenceNot enough history
Coverage9/9 companies · 123 observations
Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.
This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.
Gross debt shows contractual borrowings. Net debt subtracts reported cash; a negative value means net cash. Lower debt can create capacity, but should be read against the scale and capital intensity of the business.
Gross debtlowest gross debt
1One Global Service Provider Ltd 514330₹0 Cr
23B Blackbio DX Ltd 3BBLACKBIO⚠ unverified₹3 Cr
3Vimta Labs Ltd VIMTALABS · older report₹12 Cr
4Thyrocare Technologies Ltd THYROCARE₹51 Cr
5Suraksha Diagnostic Ltd SURAKSHA⚠ unverified₹130 Cr
Net debtlowest net debt
1Thyrocare Technologies Ltd THYROCARE₹-139 Cr
23B Blackbio DX Ltd 3BBLACKBIO⚠ unverified₹-35 Cr
3Metropolis Healthcare Ltd METROPOLIS₹29 Cr
4Suraksha Diagnostic Ltd SURAKSHA⚠ unverified₹104 Cr
5Vijaya Diagnostic Centre Ltd VIJAYA₹142 Cr
Debt and balance-sheet capacity · company comparison
9/9 level · 6/9 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Gross debt | Net debt | Reported |
|---|---|---|---|
| Krsnaa Diagnostics Ltd KRSNAA⚠ unverified | ₹534 Cr | ₹173 Cr | Mar 2026 |
| Vijaya Diagnostic Centre Ltd VIJAYA | ₹423 Cr | ₹142 Cr | Mar 2026 |
| Metropolis Healthcare Ltd METROPOLIS | ₹232 Cr | ₹29 Cr | Mar 2026 |
| Dr Lal Pathlabs Ltd 539524 | ₹199 Cr | — | Jun 2026 |
| Suraksha Diagnostic Ltd SURAKSHA⚠ unverified | ₹130 Cr | ₹104 Cr | Mar 2026 |
| Thyrocare Technologies Ltd THYROCARE | ₹51 Cr | ₹-139 Cr | Jun 2026 |
| Vimta Labs Ltd VIMTALABS | ₹12 Cr | — | Dec 2024 |
| 3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified | ₹3 Cr | ₹-35 Cr | Mar 2026 |
| One Global Service Provider Ltd 514330 | ₹0 Cr | — | Mar 2026 |
Full 20-quarter history · every available company
Gross debt · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
₹1 Cr
₹1 Cr
₹3 Cr
₹3 Cr
₹2 Cr
₹2 Cr
₹2 Cr
₹2 Cr
₹1 Cr
₹1 Cr
₹1 Cr
₹1 Cr
₹1 Cr
₹1 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹3 Cr
—
Dr Lal Pathlabs Ltd · 539524
—
—
₹533 Cr
—
—
—
₹420 Cr
—
—
—
₹247 Cr
—
—
—
₹157 Cr
—
₹149 Cr
—
₹199 Cr
—
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
₹49 Cr
₹49 Cr
₹41 Cr
₹41 Cr
₹63 Cr
₹63 Cr
₹32 Cr
₹32 Cr
₹109 Cr
₹109 Cr
₹160 Cr
₹160 Cr
₹216 Cr
₹216 Cr
₹204 Cr
₹204 Cr
₹286 Cr
₹286 Cr
₹534 Cr
—
Metropolis Healthcare Ltd · METROPOLIS
₹115 Cr
₹115 Cr
₹379 Cr
₹379 Cr
₹305 Cr
₹305 Cr
₹266 Cr
₹266 Cr
₹231 Cr
₹231 Cr
₹197 Cr
₹197 Cr
₹189 Cr
₹189 Cr
₹204 Cr
₹204 Cr
₹201 Cr
₹201 Cr
₹232 Cr
—
One Global Service Provider Ltd · 514330
—
—
₹0 Cr
—
—
—
₹0 Cr
—
—
—
₹0 Cr
—
—
—
₹0 Cr
—
₹0 Cr
—
₹0 Cr
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
₹21 Cr
—
—
—
₹99 Cr
₹97 Cr
—
—
₹92 Cr
₹89 Cr
₹85 Cr
₹85 Cr
₹89 Cr
₹89 Cr
₹118 Cr
₹118 Cr
₹130 Cr
—
Thyrocare Technologies Ltd · THYROCARE
₹23 Cr
₹22 Cr
₹21 Cr
₹21 Cr
₹18 Cr
₹20 Cr
₹23 Cr
₹23 Cr
₹47 Cr
₹47 Cr
₹42 Cr
₹42 Cr
₹19 Cr
₹19 Cr
₹25 Cr
₹25 Cr
₹25 Cr
₹25 Cr
₹51 Cr
—
Vijaya Diagnostic Centre Ltd · VIJAYA
₹167 Cr
₹167 Cr
₹183 Cr
₹183 Cr
₹230 Cr
₹230 Cr
₹248 Cr
₹248 Cr
₹253 Cr
₹253 Cr
₹259 Cr
₹259 Cr
₹292 Cr
₹292 Cr
₹320 Cr
₹320 Cr
₹365 Cr
₹365 Cr
₹423 Cr
—
Vimta Labs Ltd · VIMTALABS
—
—
₹19 Cr
—
—
—
₹15 Cr
—
—
—
₹19 Cr
—
₹12 Cr
—
—
—
—
—
—
—
Net debt · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
₹-31 Cr
₹-31 Cr
₹-26 Cr
₹-26 Cr
₹-36 Cr
₹-36 Cr
₹-4 Cr
₹-57 Cr
₹-59 Cr
₹-59 Cr
₹-13 Cr
₹-61 Cr
₹-66 Cr
₹-66 Cr
₹-12 Cr
₹-12 Cr
₹-72 Cr
₹-72 Cr
₹-35 Cr
—
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
₹-331 Cr
₹-331 Cr
₹-201 Cr
₹-201 Cr
₹-108 Cr
₹-108 Cr
₹-77 Cr
₹-77 Cr
₹-94 Cr
₹-94 Cr
₹-15 Cr
₹106 Cr
₹153 Cr
₹153 Cr
₹136 Cr
₹136 Cr
₹156 Cr
₹156 Cr
₹173 Cr
—
Metropolis Healthcare Ltd · METROPOLIS
₹-436 Cr
₹-436 Cr
₹198 Cr
₹198 Cr
₹168 Cr
₹168 Cr
₹184 Cr
₹172 Cr
₹124 Cr
₹124 Cr
₹73 Cr
₹81 Cr
₹4 Cr
₹4 Cr
₹86 Cr
₹86 Cr
₹121 Cr
₹121 Cr
₹29 Cr
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
₹42 Cr
—
—
₹35 Cr
₹31 Cr
₹28 Cr
₹28 Cr
₹69 Cr
₹69 Cr
₹74 Cr
₹74 Cr
₹104 Cr
—
Thyrocare Technologies Ltd · THYROCARE
₹-88 Cr
₹-95 Cr
₹-118 Cr
₹-118 Cr
₹-87 Cr
₹-100 Cr
₹-117 Cr
₹-117 Cr
₹-52 Cr
₹-52 Cr
₹-104 Cr
₹-135 Cr
₹-119 Cr
₹-119 Cr
₹-130 Cr
₹-130 Cr
₹-167 Cr
₹-167 Cr
₹-139 Cr
—
Vijaya Diagnostic Centre Ltd · VIJAYA
₹-52 Cr
₹-52 Cr
₹-42 Cr
₹-64 Cr
₹-19 Cr
₹-19 Cr
₹-7 Cr
₹-7 Cr
₹-45 Cr
₹-45 Cr
₹74 Cr
₹77 Cr
₹81 Cr
₹81 Cr
₹39 Cr
₹87 Cr
₹68 Cr
₹68 Cr
₹142 Cr
—
06 · compare level, then change
Return On Capital Employed
One Global Service Provider Ltd has the highest ROCE among the 9 Diagnostics companies compared here, at 87%. Thyrocare Technologies Ltd is next at 35.4%. The same company also holds the highest ROCE change, at +31 percentage points. 9 of 9 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: One Global Service Provider Ltd leads ROCE at 87%, 51.6 percentage points above Thyrocare Technologies Ltd. One Global Service Provider Ltd has the strongest latest improvement at +31 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderOne Global Service Provider Ltd · 87%
Gap145.8% versus #2 · Thyrocare Technologies Ltd
PersistenceNot enough history
Coverage9/9 companies · 86 observations
Investor read: One Global Service Provider Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1One Global Service Provider Ltd 51433087%
2Thyrocare Technologies Ltd THYROCARE35%
3Dr Lal Pathlabs Ltd 53952428%
43B Blackbio DX Ltd 3BBLACKBIO⚠ unverified26%
5Vijaya Diagnostic Centre Ltd VIJAYA21%
ROCE changefastest improvers
1One Global Service Provider Ltd 514330+31.0 pp
2Thyrocare Technologies Ltd THYROCARE+8.3 pp
3Metropolis Healthcare Ltd METROPOLIS+2.4 pp
4Vijaya Diagnostic Centre Ltd VIJAYA−0.5 pp
5Dr Lal Pathlabs Ltd 539524−1.0 pp
Return on capital · company comparison
9/9 level · 9/9 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
Withheld from this chart: Vimta Labs Ltd (VIMTALABS) — its two data sources disagree by up to 64% on reported income across 13 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Thyrocare Technologies Ltd THYROCARE | 32% | +8.3 pp | Jun 2026 |
| Vijaya Diagnostic Centre Ltd VIJAYA | 18% | −0.5 pp | Mar 2026 |
| 3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified | 15% | −2.6 pp | Mar 2026 |
| Metropolis Healthcare Ltd METROPOLIS | 15% | +2.4 pp | Mar 2026 |
| Suraksha Diagnostic Ltd SURAKSHA⚠ unverified | 14% | −2.1 pp | Mar 2026 |
| Krsnaa Diagnostics Ltd KRSNAA⚠ unverified | 7.8% | −2.6 pp | Mar 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
39%
—
25%
—
18%
—
15%
—
12%
19%
14%
23%
18%
28%
18%
26%
15%
26%
15%
—
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
12%
—
12%
—
9.4%
—
8.5%
—
7.7%
10%
7.8%
11%
9.9%
14%
10%
14%
11%
14%
7.8%
—
Metropolis Healthcare Ltd · METROPOLIS
34%
—
23%
—
18%
—
17%
—
15%
15%
15%
16%
16%
17%
12%
15%
13%
16%
15%
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
—
—
16%
17%
17%
18%
16%
19%
14%
18%
14%
—
Thyrocare Technologies Ltd · THYROCARE
45%
41%
37%
—
21%
18%
15%
—
16%
18%
17%
20%
21%
25%
24%
30%
31%
37%
32%
—
Vijaya Diagnostic Centre Ltd · VIJAYA
27%
—
23%
—
17%
—
15%
—
17%
22%
18%
22%
19%
23%
18%
23%
17%
22%
18%
—
ROCE change · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
—
—
—
—
−21.0 pp
—
−10.2 pp
—
−5.8 pp
—
−0.4 pp
—
+5.8 pp
+8.4 pp
+3.7 pp
+2.8 pp
−2.3 pp
−1.5 pp
−2.6 pp
—
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
—
—
—
—
−2.8 pp
—
−3.5 pp
—
−1.7 pp
—
−0.7 pp
—
+2.2 pp
+3.4 pp
+2.6 pp
+3.0 pp
+0.9 pp
−0.1 pp
−2.6 pp
—
Metropolis Healthcare Ltd · METROPOLIS
—
—
—
—
−16.2 pp
—
−6.4 pp
—
−2.8 pp
—
−1.6 pp
—
+0.2 pp
+1.7 pp
−2.5 pp
−1.1 pp
−2.9 pp
−1.0 pp
+2.4 pp
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
−0.1 pp
+2.2 pp
−2.6 pp
−0.3 pp
−2.1 pp
—
Thyrocare Technologies Ltd · THYROCARE
—
—
—
—
−24.0 pp
−23.1 pp
−22.2 pp
—
−4.8 pp
−0.2 pp
+1.8 pp
—
+5.1 pp
+6.8 pp
+7.1 pp
+9.9 pp
+10.1 pp
+12.8 pp
+8.3 pp
—
Vijaya Diagnostic Centre Ltd · VIJAYA
—
—
—
—
−10.0 pp
—
−8.0 pp
—
−0.7 pp
—
+2.7 pp
—
+2.1 pp
+0.9 pp
+0.2 pp
+0.4 pp
−1.5 pp
−1.2 pp
−0.5 pp
—
07 · compare level, then change
Valuation Against Growth & Quality
Thyrocare Technologies Ltd has the lowest Guarded PEG among the 9 Diagnostics companies compared here, at 1.1×. Vijaya Diagnostic Centre Ltd is next at 1.46×. One Global Service Provider Ltd has the lowest P/E at 16.6×, so level and change sit with different companies. 3 of 9 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Thyrocare Technologies Ltd has the lowest comparable Guarded PEG at 1.1×, 24.7% below Vijaya Diagnostic Centre Ltd. Only 3 of 9 companies pass the guard, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderThyrocare Technologies Ltd · 1.1×
Gap24.7% versus #2 · Vijaya Diagnostic Centre Ltd
Persistence0/8 recent comparable periods
Coverage3/9 companies · 23 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data sources reconciled. A missing PEG is more honest than a low-base fiction.
Guarded PEGlowest PEG
1Thyrocare Technologies Ltd THYROCARE1.1
2Vijaya Diagnostic Centre Ltd VIJAYA1.5
3Metropolis Healthcare Ltd METROPOLIS2.3
P/Elowest P/E
1One Global Service Provider Ltd 51433016.6
2Krsnaa Diagnostics Ltd KRSNAA⚠ unverified17.4
33B Blackbio DX Ltd 3BBLACKBIO⚠ unverified18.7
4Suraksha Diagnostic Ltd SURAKSHA⚠ unverified40.9
5Vimta Labs Ltd VIMTALABS · older report41.9
Valuation · company comparison
3/9 level · 9/9 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Guarded PEG | P/E | Reported |
|---|---|---|---|
| Metropolis Healthcare Ltd METROPOLIS | 2.3 | 51.0 | Mar 2026 |
| Vijaya Diagnostic Centre Ltd VIJAYA | 1.5 | 55.6 | Mar 2026 |
| Thyrocare Technologies Ltd THYROCARE | 1.1 | 51.2 | Jun 2026 |
| One Global Service Provider Ltd 514330 | — | 20.0 | Mar 2026 |
| Dr Lal Pathlabs Ltd 539524 | — | 53.9 | Jun 2026 |
| Vimta Labs Ltd VIMTALABS | — | 39.8 | Dec 2024 |
| Krsnaa Diagnostics Ltd KRSNAA⚠ unverified | — | 22.1 | Mar 2026 |
| Suraksha Diagnostic Ltd SURAKSHA⚠ unverified | — | 36.9 | Mar 2026 |
| 3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified | — | 17.4 | Mar 2026 |
Full 20-quarter history · every available company
Guarded PEG · reported quarter history
Metropolis Healthcare Ltd · METROPOLIS
—
—
—
3.5
—
—
—
—
—
—
7.7
—
—
4.7
—
—
—
2.3
—
—
Thyrocare Technologies Ltd · THYROCARE
—
—
—
—
—
—
—
—
—
—
1.0
4.8
1.9
2.0
1.2
2.0
1.5
1.1
—
—
Vijaya Diagnostic Centre Ltd · VIJAYA
—
—
—
—
—
—
3.0
—
—
4.5
1.4
1.5
2.1
2.8
3.1
3.6
3.4
5.2
1.5
—
P/E · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
4.0
8.0
9.3
8.8
13.0
15.6
13.4
12.7
20.9
21.4
20.2
27.6
30.0
39.7
28.9
25.8
23.9
24.4
17.4
—
Dr Lal Pathlabs Ltd · 539524
82.2
78.8
59.9
49.0
77.4
76.0
62.6
78.8
79.8
71.3
57.2
64.9
71.6
61.4
49.7
47.9
52.1
44.0
40.5
53.9
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
-57.5
58.7
22.4
23.9
25.7
22.7
23.6
29.6
34.2
38.4
34.0
34.0
44.3
40.5
33.6
29.0
32.0
28.0
22.1
—
Metropolis Healthcare Ltd · METROPOLIS
64.1
72.8
45.5
36.4
46.0
43.9
42.8
53.5
54.1
64.5
70.8
79.2
81.7
71.3
54.2
68.2
74.6
71.1
51.0
—
One Global Service Provider Ltd · 514330
5.6
7.4
17.8
32.5
22.5
20.9
13.0
16.6
15.9
10.8
15.6
14.3
16.2
25.9
22.9
14.2
10.7
24.3
20.0
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
2.2
2.4
48.5
43.8
44.2
36.9
—
Thyrocare Technologies Ltd · THYROCARE
39.8
28.8
21.4
18.9
26.1
41.0
31.1
42.5
50.1
52.5
47.6
47.6
55.7
58.5
41.0
57.6
56.0
57.4
40.5
51.2
Vijaya Diagnostic Centre Ltd · VIJAYA
31.2
31.3
23.6
30.8
49.9
49.7
49.4
57.0
54.6
66.8
56.9
63.6
71.8
82.0
72.7
70.4
69.1
69.6
55.6
—
Vimta Labs Ltd · VIMTALABS
19.7
26.2
19.0
17.0
16.2
19.8
14.7
18.8
26.5
20.7
21.7
25.9
26.1
39.8
—
—
—
—
—
—
08 · compare level, then change
Enterprise Value & Book Value
Krsnaa Diagnostics Ltd has the lowest EV/EBITDA among the 9 Diagnostics companies compared here, at 8.5×. 3B Blackbio DX Ltd is next at 12.2×. The same company also holds the lowest P/BV, at 1.8×. 9 of 9 companies report a comparable reading, the latest through Mar 2026. Its EV/EBITDA series carries 19 reported observations across the 20-quarter window.
What the numbers say: Krsnaa Diagnostics Ltd leads both ev/ebitda at 8.5× and p/bv at 1.8×.
LeaderKrsnaa Diagnostics Ltd · 8.5×
Gap30.3% versus #2 · 3B Blackbio DX Ltd
Persistence0/8 recent comparable periods
Coverage9/9 companies · 155 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.
EV/EBITDA includes debt in enterprise value and is useful across different capital structures. P/BV prices the company against its own book. Both are market multiples on reported figures, not intrinsic-value estimates and not forecasts.
EV/EBITDAlowest EV/EBITDA
1Krsnaa Diagnostics Ltd KRSNAA⚠ unverified8.5
23B Blackbio DX Ltd 3BBLACKBIO⚠ unverified12.2
3Suraksha Diagnostic Ltd SURAKSHA⚠ unverified13.9
4Vimta Labs Ltd VIMTALABS · older report20.6
5Metropolis Healthcare Ltd METROPOLIS23.9
P/BVlowest P/BV
1Krsnaa Diagnostics Ltd KRSNAA⚠ unverified1.8
23B Blackbio DX Ltd 3BBLACKBIO⚠ unverified3.4
3Suraksha Diagnostic Ltd SURAKSHA⚠ unverified5.4
4Vimta Labs Ltd VIMTALABS · older report7.4
5Metropolis Healthcare Ltd METROPOLIS7.8
Enterprise and book valuation · company comparison
9/9 level · 9/9 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | EV/EBITDA | P/BV | Reported |
|---|---|---|---|
| One Global Service Provider Ltd 514330 | 38.6 | 9.9 | Mar 2026 |
| Dr Lal Pathlabs Ltd 539524 | 31.3 | 12.5 | Jun 2026 |
| Thyrocare Technologies Ltd THYROCARE | 30.2 | 14.1 | Jun 2026 |
| Vijaya Diagnostic Centre Ltd VIJAYA | 27.8 | 10.3 | Mar 2026 |
| Metropolis Healthcare Ltd METROPOLIS | 23.9 | 6.2 | Mar 2026 |
| Vimta Labs Ltd VIMTALABS | 20.6 | 6.5 | Dec 2024 |
| Suraksha Diagnostic Ltd SURAKSHA⚠ unverified | 13.9 | 5.3 | Mar 2026 |
| 3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified | 12.2 | 3.4 | Mar 2026 |
| Krsnaa Diagnostics Ltd KRSNAA⚠ unverified | 8.5 | 1.9 | Mar 2026 |
Full 20-quarter history · every available company
EV/EBITDA · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
2.4
4.8
5.5
4.9
7.0
9.3
8.0
8.0
13.5
16.0
15.1
19.9
21.1
27.7
19.9
17.9
16.6
16.7
12.2
—
Dr Lal Pathlabs Ltd · 539524
50.1
47.8
34.1
27.4
38.7
34.9
28.3
35.3
36.8
34.5
28.5
33.4
37.8
32.6
26.5
28.8
31.9
27.1
24.8
31.3
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
22.3
14.8
9.4
9.8
10.9
10.0
9.3
11.6
14.2
15.0
12.3
11.7
15.2
15.3
13.1
10.4
12.2
11.0
8.5
—
Metropolis Healthcare Ltd · METROPOLIS
39.4
44.0
25.8
19.6
25.0
22.3
21.1
25.9
25.7
30.1
32.0
35.3
36.9
33.0
25.4
30.6
33.5
31.9
23.9
—
One Global Service Provider Ltd · 514330
5.2
6.6
14.2
24.8
17.4
17.0
11.4
14.0
12.7
8.4
11.5
10.5
11.8
19.1
16.8
10.4
19.9
47.0
38.6
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
24.5
16.1
20.7
18.4
16.8
13.9
—
Thyrocare Technologies Ltd · THYROCARE
26.2
20.0
14.8
12.6
16.8
22.0
16.2
21.2
23.4
25.4
22.7
22.9
27.5
29.0
19.9
25.9
26.9
29.8
21.8
30.2
Vijaya Diagnostic Centre Ltd · VIJAYA
32.9
33.3
25.0
15.3
23.9
23.0
20.6
24.6
25.3
32.2
29.1
32.3
36.5
41.9
37.3
35.5
35.0
34.8
27.8
—
Vimta Labs Ltd · VIMTALABS
9.6
13.1
9.9
8.9
8.2
10.0
7.2
8.9
12.7
9.6
10.4
11.6
12.7
20.6
—
—
—
—
—
—
P/BV · reported quarter history
3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified
2.7
2.3
2.0
1.9
1.6
2.2
2.0
2.1
3.0
2.9
3.2
4.4
5.1
7.0
5.6
5.5
4.4
4.0
3.4
—
Dr Lal Pathlabs Ltd · 539524
26.0
23.2
16.0
11.3
13.6
12.2
10.2
12.5
12.6
12.1
10.7
12.6
14.8
12.3
10.3
10.7
12.3
9.9
9.3
12.5
Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified
3.8
3.6
2.5
2.4
2.2
2.0
2.1
2.7
2.9
2.9
2.6
2.6
3.3
3.3
3.0
2.8
2.9
2.6
1.9
—
Metropolis Healthcare Ltd · METROPOLIS
22.1
20.8
12.1
10.4
8.3
7.1
7.2
8.6
7.6
8.2
8.4
10.2
10.2
8.9
6.8
7.9
7.8
6.9
6.2
—
One Global Service Provider Ltd · 514330
5.6
2.9
4.8
6.9
3.6
3.9
3.8
3.9
4.8
3.2
6.2
14.0
8.9
13.3
14.3
6.1
2.7
12.0
9.9
—
Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
9.9
6.8
8.2
7.3
6.1
5.3
—
Thyrocare Technologies Ltd · THYROCARE
15.7
11.6
8.2
7.8
7.5
6.7
4.3
5.2
5.6
7.0
6.4
6.3
8.2
10.1
7.4
10.0
10.9
13.7
10.8
14.1
Vijaya Diagnostic Centre Ltd · VIJAYA
13.8
14.1
10.6
7.2
9.4
8.9
8.5
10.3
9.3
11.6
10.9
14.0
13.7
15.2
14.3
15.4
13.2
12.3
10.3
—
Vimta Labs Ltd · VIMTALABS
3.2
4.3
3.5
3.1
2.9
3.8
3.0
3.2
4.5
3.0
3.3
3.3
3.8
6.5
—
—
—
—
—
—
09 · let price answer last
Market action
One Global Service Provider Ltd has the strongest one-year price move in Diagnostics at +135.5%. Vijaya Diagnostic Centre Ltd leads on Mansfield relative strength against NIFTY at +23.2%. 4 of 8 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-17.
Every price line is indexed to 100 over the chosen window. Mansfield relative strength compares a price ratio with its own 52-week average; zero separates leadership from lagging.
Price and relative strength
Price is rebased to 100 inside the selected window. Pair ratio rebases each selected company against one chosen denominator.
Before the conclusion · check the blind spots
What can make this comparison misleading?
This Diagnostics comparison names 8 specific ways its own evidence can mislead, all listed below. 1 of the 9 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. 3 draw at least one figure from a second feed with too little overlap to cross-check.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
- 3 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
- 1 company is missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
- Thin comparisons: Capital expenditure have fewer than three usable current readings.
10 · the complete set
Which companies are included?
All 9 companies in the canonical Diagnostics membership are listed below, largest market value first — nothing is silently dropped, even where a company reports too little to rank. The charts above default to a selective view; this register is the complete set, with each company's own latest reporting date beside it.
AHEAD means the company is beating the index by 5% or more over three months. LAGGING, FUNDAMENTALS UP means it is 20% or more behind over a year while its trailing twelve-month earnings grew 20% or more. Both rules are fixed and applied the same way in every sector.
| Company | Market value | Price | Priced to | Latest fundamentals | Source standing |
|---|---|---|---|---|---|
| Dr Lal Pathlabs Ltd 539524 | ₹30.7K Cr | ₹1,827 | — | Jun 2026 | Primary source only |
| Vijaya Diagnostic Centre Ltd VIJAYAAHEAD22/26 WEEKS | ₹13.5K Cr | ₹1,314 | 2026-07-19 | Mar 2026 | Cross-checked |
| Metropolis Healthcare Ltd METROPOLISAHEAD22/26 WEEKS | ₹11.8K Cr | ₹570 | 2026-07-19 | Mar 2026 | Cross-checked |
| Thyrocare Technologies Ltd THYROCAREAHEAD | ₹9.0K Cr | ₹564 | 2026-07-19 | Jun 2026 | Cross-checked |
| Vimta Labs Ltd VIMTALABSAHEAD | ₹2.5K Cr | ₹570 | 2026-07-19 | Dec 2024 | Second feed withheld |
| Krsnaa Diagnostics Ltd KRSNAALAGGING, FUNDAMENTALS UP⚠ unverified | ₹1.8K Cr | ₹545 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| Suraksha Diagnostic Ltd SURAKSHA⚠ unverified | ₹1.3K Cr | ₹253 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| One Global Service Provider Ltd 514330 | ₹1.2K Cr | ₹590 | 2026-07-19 | Mar 2026 | Primary source only |
| 3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified | ₹1.1K Cr | ₹1,278 | 2026-07-19 | Mar 2026 | Includes unverified figures |
How each company's sources stand: 3 of 9 companies draw at least one figure from a second data feed that could not be cross-checked against the primary source, because the two do not share enough reported history to compare. Those figures are marked unverified wherever they appear. 1 of 9 companies has a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Vimta Labs Ltd (VIMTALABS) — its two data sources disagree by up to 64% on reported income across 13 comparable periods, so its derived ratios are withheld.
Evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 9 Diagnostics companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-07-24. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-07-24 · weekly price and relative-strength history
Derived metricsGrowth, changes, CAPEX intensity, net debt, guarded PEG and P/BV÷ROE are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing3 cross-checked · 5 unverified · 1 withheld, of 9 graded companies.
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from. Every company's standing is listed in the register above.
Questions investors ask · short, speakable answers
Diagnostics company comparison FAQs
These 18 answers restate the Diagnostics comparison above in question form. Every one is computed from the same 9 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-07-24. Nothing here is estimated, and none of it is a recommendation.
What is the Nifty Diagnostics index?
The Nifty Diagnostics index tracks India's listed Diagnostics companies as a single basket. This page follows the same 9 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Diagnostics sector rather than to its largest constituent. Figures are as of Jun 2026.
Which are the best Diagnostics stocks in India?
Ranked by this page's four-factor score, Thyrocare Technologies Ltd places first among 9 listed Diagnostics companies, followed by One Global Service Provider Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Diagnostics stocks are listed in India?
This comparison covers 9 listed Diagnostics companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Diagnostics company is the biggest?
Dr Lal Pathlabs Ltd is the largest, with trailing-twelve-month revenue of ₹2,892 crore, ahead of Metropolis Healthcare Ltd at ₹1,646 crore. That covers 9 of 9 companies with comparable reporting through Jun 2026.
Which Diagnostics company is growing fastest?
One Global Service Provider Ltd has the fastest revenue growth at 100% year on year, across 9 of 9 comparable companies. Fast growth off a small base is not the same as proven scale — check whether the rate holds across several quarters on the chart above before treating it as a trend.
Which Diagnostics company has the best profit margins?
Vijaya Diagnostic Centre Ltd has the highest operating margin at 44%, from 9 of 9 comparable companies. Metropolis Healthcare Ltd shows the biggest recent improvement, at +7 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Diagnostics company makes the most profit?
Dr Lal Pathlabs Ltd earns the most, at ₹545 crore of trailing-twelve-month net profit, from 9 of 9 comparable companies. One Global Service Provider Ltd has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Diagnostics company earns the highest return on capital?
One Global Service Provider Ltd leads on return on capital employed at 87%, across 9 of 9 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Diagnostics stock is the cheapest?
On guarded PEG — where a LOWER number is cheaper — Thyrocare Technologies Ltd screens cheapest at 1.1×. Only 3 of 9 companies pass the comparability guard, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Which Diagnostics company has the strongest balance sheet?
One Global Service Provider Ltd carries the lowest comparable gross debt at ₹0 crore, from 9 of 9 companies. Absolute rupee debt alone does not settle it, because company scale differs — net debt and debt-to-equity in the chart above carry more information, and a very low-debt balance sheet can also mean under-investment.
Which Diagnostics stock has the strongest price momentum?
Vijaya Diagnostic Centre Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Diagnostics company scores highest for research priority?
Thyrocare Technologies Ltd scores 74 out of 100 with 97% evidence confidence, from 27.4 points on growth and earnings, 16.9 on capital efficiency, 12.3 on valuation and 17.4 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Diagnostics companies does this comparison cover, and over what period?
It compares 9 listed companies over up to 20 reported quarters of fundamentals and 10 fiscal years of capital allocation, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Diagnostics sector?
The 9 Diagnostics companies on this page carry ₹72,893 crore of combined market value. Dr Lal Pathlabs Ltd is the largest at ₹30,674 crore, about 42% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-07-29.
What is the Diagnostics sector's P/E ratio?
The median price-to-earnings ratio across the 9 Diagnostics companies on this page is 41.9×, measured on the 9 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-07-29.
How is the Diagnostics sector performing?
4 of the 8 covered Diagnostics companies are beating NIFTY 500 on Mansfield relative strength. A 52-week sector-versus-index comparison is not available from the current market series for this sector, so it is not quoted. Readings are as of 2026-07-29.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.